— Know what they know.
Not Investment Advice

UNCY

Unicycive Therapeutics, Inc.
1W: -1.6% 1M: -3.5% 3M: +13.7% YTD: +14.7% 1Y: +3.4% 3Y: -69.6%
$6.65
+0.26 (+4.07%)
After Hours: $6.67 (+0.01, +0.23%)
NASDAQ · Healthcare · Biotechnology · $142.9M · Alpha Radar Buy · Power 52
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$142.9M
52W Range3.71-11
Volume482,618
Avg Volume537,227
Beta1.82
Dividend
Analyst Ratings
5 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOShalabh K. Gupta
Employees22
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-12
4300 El Camino Real
Los Altos, CA 94022
US
650 351 4495
About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Recent Insider Trades

NameTypeSharesPriceDate
Aggarwal Gaurav C-Conversion 652,900 2025-08-25
Aggarwal Gaurav D-Return 3,199 $4.90 2025-08-25
Aggarwal Gaurav A-Award 21,200 $4.71 2025-07-28
Laumas Sandeep A-Award 21,200 $4.71 2025-07-28
Kenkare-Mitra Sara A-Award 21,200 $4.71 2025-07-28

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms